Fintelmann Robert E, Hoskins Eliza N, Lietman Thomas M, Keenan Jeremy D, Gaynor Bruce D, Cevallos Vicky, Acharya Nisha R
Francis I. Proctor Foundation for Research in Ophthalmology, University of California-San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0412, USA.
Arch Ophthalmol. 2011 Apr;129(4):399-402. doi: 10.1001/archophthalmol.2011.45.
To determine whether recent use of topical fluoroquinolones is a risk factor for in vitro fluoroquinolone resistance in Staphylococcus aureus ocular isolates.
Disk diffusion susceptibility testing for ciprofloxacin, moxifloxacin, and gatifloxacin was performed for all ocular isolates of S aureus at the Francis I. Proctor Foundation microbiology laboratory from January 1, 2005, to December 31, 2008. The medical records of patients with positive S aureus cultures were reviewed to determine topical or systemic fluoroquinolone use within the 3 months prior to culture. The Fisher exact test was used to compare the proportion of patients who used topical fluoroquinolones in the past 3 months among fluoroquinolone-sensitive and -resistant cases. Logistic regression was used to determine risk factors for fluoroquinolone resistance.
Of 200 S aureus cultures, 41 were resistant to ciprofloxacin, moxifloxacin, and gatifloxacin (20.5%). Fluoroquinolone-resistant S aureus isolates were from older patients (mean [SD] age, 65.5 [25.0] years) compared with fluoroquinolone-susceptible isolates (mean [SD] patient age, 52.1 [22.1] years) (P = .003). Use of fluoroquinolones within the 3 months before testing was more frequent in resistant isolates (29%) than in susceptible isolates (11%) (P = .005), as was recent hospitalization (22% of resistant isolates, 0% of susceptible isolates) (P < .001). In the multivariate regression analysis, topical fluoroquinolone use within 3 months was a significant predictor of fluoroquinolone resistance (P = .046), along with age, systemic immunosuppression, and topical fluoroquinolone use between 3 and 6 months before testing.
Recent topical fluoroquinolone use is significantly associated with fluoroquinolone resistance in S aureus isolates from ocular cultures.
确定近期使用局部氟喹诺酮类药物是否是金黄色葡萄球菌眼部分离株对氟喹诺酮类药物体外耐药的危险因素。
2005年1月1日至2008年12月31日期间,在弗朗西斯一世普罗克特基金会微生物实验室对所有金黄色葡萄球菌眼部分离株进行了环丙沙星、莫西沙星和加替沙星的纸片扩散药敏试验。对金黄色葡萄球菌培养阳性患者的病历进行回顾,以确定培养前3个月内局部或全身使用氟喹诺酮类药物的情况。采用Fisher精确检验比较氟喹诺酮类药物敏感和耐药病例中过去3个月使用局部氟喹诺酮类药物的患者比例。采用逻辑回归分析确定氟喹诺酮类药物耐药的危险因素。
在200株金黄色葡萄球菌培养物中,41株对环丙沙星、莫西沙星和加替沙星耐药(20.5%)。与氟喹诺酮类药物敏感的分离株(平均[标准差]年龄,52.1[22.1]岁)相比,氟喹诺酮类药物耐药的金黄色葡萄球菌分离株来自年龄较大的患者(平均[标准差]年龄,65.5[25.0]岁)(P = 0.003)。耐药分离株在检测前3个月内使用氟喹诺酮类药物的频率(29%)高于敏感分离株(11%)(P = 0.005),近期住院情况也是如此(耐药分离株为22%,敏感分离株为0%)(P < 0.001)。在多变量回归分析中,检测前3个月内局部使用氟喹诺酮类药物是氟喹诺酮类药物耐药的显著预测因素(P = 0.046),同时还有年龄、全身免疫抑制以及检测前3至6个月内局部使用氟喹诺酮类药物。
近期局部使用氟喹诺酮类药物与眼部培养物中金黄色葡萄球菌分离株对氟喹诺酮类药物耐药显著相关。